Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Alexia Covington

Nurse Practitioner Atlanta, GA Nurse Practitioner

NPI 1841948791 CMS profile 11377693

415 Armour Dr Ne Apt 1410, Atlanta, GA 30324

Open in the dashboard

General payments

$12,812

585 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexia Covington of Atlanta, GA is reported in the CMS Open Payments database as having received $12,812 across 585 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,860 177
2024 General $2,742 134
2023 General $4,133 182
2022 General $2,077 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexia Covington
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alexia Covington were reported at $3,860. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alexia Covington Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $2,077 $152 $48–$470 $149
2023 $4,133 $166 $54–$529 $160
2024 $2,742 $173 $55–$556 $164
2025 $3,860 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $5,191 223 payments
  2. Amgen Inc. $1,465 68 payments
  3. Novartis Pharmaceuticals Corporation $1,053 56 payments
  4. Janssen Biotech, Inc. $837 42 payments
  5. UCB, Inc. $689 42 payments
  6. AstraZeneca Pharmaceuticals LP $614 22 payments
  7. ANI Pharmaceuticals, Inc. $356 17 payments
  8. Radius Health, Inc. $347 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $306 12 payments
  10. Pfizer Inc. $249 14 payments
  11. Other $1,705 74 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $12,738 583 payments
  2. Education $74 2 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $4,114 177 payments
  2. COSENTYX $926 53 payments
  3. SKYRIZI Immunology $779 36 payments
  4. TREMFYA $736 37 payments
  5. Enbrel $721 33 payments
  6. SAPHNELO $540 19 payments
  7. Otezla $529 22 payments
  8. OFEV $380 15 payments
  9. SIMPONI ARIA $347 15 payments
  10. SKYRIZI Immunology $340 12 payments
  11. Other $4,624 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

997

Median for Nurse Practitioner: 389

Drug cost

$1,111,457

Median for Nurse Practitioner: $21,885

Branded share of claims

25%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 33 $210,458
Humira(Cf) Pen Adalimumab Brand 24 $202,298
Xeljanz Xr Tofacitinib Citrate Brand 33 $194,071
Orencia Clickject Abatacept Brand 19 $136,441
Enbrel Mini Etanercept Brand 15 $116,518
Enbrel Sureclick Etanercept Brand 11 $80,865
Simponi Golimumab Brand 13 $77,824
Otezla Apremilast Brand 16 $75,500
Hydroxychloroquine Sulfate Generic 106 $5,449
Sulfasalazine Generic 64 $1,846

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $703
$703 33 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $301
$301 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $188
$188 — —
TREMFYA
  • Janssen Biotech, Inc. $186
$186 — —
Enbrel
  • Amgen Inc. $182
$182 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

585 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record